Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.

Paulzen M, Haen E, Hiemke C, Stegmann B, Lammertz SE, Gründer G, Schoretsanitis G.

Br J Clin Pharmacol. 2017 Aug;83(8):1668-1675. doi: 10.1111/bcp.13255. Epub 2017 Mar 2.

PMID:
28160505
2.

Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU.

World Psychiatry. 2017 Feb;16(1):77-89. doi: 10.1002/wps.20387.

3.

Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria.

Igbinomwanhia NG, Olotu SO, James BO.

Ther Adv Psychopharmacol. 2017 Jan;7(1):3-10. doi: 10.1177/2045125316672134. Epub 2016 Oct 13.

4.

Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.

Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G.

Schizophr Bull. 2017 Jan 1. pii: sbw171. doi: 10.1093/schbul/sbw171. [Epub ahead of print]

PMID:
28044008
5.

Effect of pharmacist intervention on physician prescribing in patients with chronic schizophrenia: a descriptive pre/post study.

Hashimoto Y, Tensho M.

BMC Health Serv Res. 2016 Apr 26;16:150. doi: 10.1186/s12913-016-1408-4.

6.

A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.

Gaviria AM, Franco JG, Aguado V, Rico G, Labad J, de Pablo J, Vilella E.

PLoS One. 2015 Oct 1;10(10):e0139403. doi: 10.1371/journal.pone.0139403. eCollection 2015.

7.

Concomitant use of two or more antipsychotic drugs is common in Sweden.

Bergendal A, Schiöler H, Wettermark B, Björkstén KS.

Ther Adv Psychopharmacol. 2015 Aug;5(4):224-31. doi: 10.1177/2045125315588647.

8.

The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release.

Lee HW, Na KS, Jung SH, Kang MH, Lee JS, Bae JN, Kim HY, Kim CE.

Clin Psychopharmacol Neurosci. 2013 Dec;11(3):152-7. doi: 10.9758/cpn.2013.11.3.152. Epub 2013 Dec 24.

9.

Cost prediction of antipsychotic medication of psychiatric disorder using artificial neural network model.

Mirabzadeh A, Bakhshi E, Khodae MR, Kooshesh MR, Mahabadi BR, Mirabzadeh H, Biglarian A.

J Res Med Sci. 2013 Sep;18(9):782-5.

10.

Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study.

Eriksson L, Hallerbäck T, Jørgensen L, Carlborg A.

Ther Adv Psychopharmacol. 2012 Dec;2(6):217-26. doi: 10.1177/2045125312453935.

11.

Polypharmacy in psychiatry: a review.

Kukreja S, Kalra G, Shah N, Shrivastava A.

Mens Sana Monogr. 2013 Jan;11(1):82-99. doi: 10.4103/0973-1229.104497.

12.

Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU.

Psychiatry Res. 2013 Oct 30;209(3):406-11. doi: 10.1016/j.psychres.2013.03.014. Epub 2013 Apr 18.

13.

Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Correll CU, Gallego JA.

Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24. Review.

14.

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.

Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR.

Neuropsychiatr Dis Treat. 2012;8:259-66. doi: 10.2147/NDT.S25662. Epub 2012 Jun 18.

15.

Antipsychotic polypharmacy in a regional health service: a population-based study.

Bernardo M, Coma A, Ibáñez C, Zara C, Bari JM, Serrano-Blanco A.

BMC Psychiatry. 2012 May 15;12:42. doi: 10.1186/1471-244X-12-42.

16.

Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU.

Schizophr Res. 2012 Jun;138(1):18-28. doi: 10.1016/j.schres.2012.03.018. Epub 2012 Apr 24. Review.

17.

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.

Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M.

Clinicoecon Outcomes Res. 2012;4:13-9. doi: 10.2147/CEOR.S25968. Epub 2012 Jan 13.

18.

Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.

Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, Shida H, Oguchi Y, Okumura Y, Ito H, Kayama M, Kashima H.

BMC Psychiatry. 2011 Jul 26;11:118. doi: 10.1186/1471-244X-11-118.

19.

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2.

20.

Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.

Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM.

Schizophr Res. 2011 Sep;131(1-3):58-62. doi: 10.1016/j.schres.2011.02.016. Epub 2011 Mar 21.

Supplemental Content

Support Center